Pfizer is developing a hybrid vaccine that combines its original shot with a formulation that shields against the highly transmissible Omicron variant.
While research continues, Pfizer will evaluate the new hybrid formulation against an Omicron-specific shot and determine which is best suited to move forward by March, CEO Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Pfizer will be ready in March to approach US regulators for clearance of the modified vaccine and bring it to market, and it has already begun production, Bourla said.
Pfizer said at the end of November, shortly after the new strain was first detected in SA, that it was working on a stand-alone Omicron-specific vaccine.
Pfizer is also making inroads in scaling out access to its oral Covid-19 treatment, Paxlovid.
The New York-based drug giant and German partner BioNTech are also testing higher-dose versions of their vaccine and evaluating different dosing schedules, Bourla said. He added that he continues to provide additional resources to the company’s vaccine unit and is also looking to deploy its messenger RNA technology in other spaces.
“Clearly [mRNA] is a very powerful technology and we’re just scratching the surface of,” he said.
On Monday, Pfizer announced a trio of deals to build out its budding franchise of mRNA candidates to target Covid-19, rare diseases and cancer.
Pfizer is also making inroads in scaling out access to its oral Covid-19 treatment, Paxlovid. “In a couple of weeks we will have it everywhere,” Bourla said of US access to the pill.
More stories like this are available on bloomberg.com
— Bloomberg
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.